Skip to main content

Table 1 Results of blood culture testing of IBD and non-IBD patients (January 2017–December 2019)

From: Are hospitalized patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 3-year cohort study

Number of blood cultures performed in IBD patients n Positive results n/% Microorganisms cultured Number %In relation to all samples taken %In relation to positive results
Results of blood culture testing of IBD patients
24 10/41.7% Staphylococcus epidermidis MRCNS 4 16.7% 40.0%
Staphylococcus aureus 1 4.2% 10.0%
Escherichia coli 3 12.5% 30.0%
Cutibacterium acnes 1 4.2% 10.0%
Micrococcus luteus 1 4.2% 10.0%
Results of blood culture testing of non-IBD patients
844 77/9.1% Staphylococcus epidermidis MRCNS 33 3.9% 42.8%
Staphylococcus epidermidis 9 1.1% 11.7%
Staphylococcus aureus MRSA 2 0.24% 2.6%
Staphylococcus aureus 2 0.24% 2.6%
Enterococcus faecium 4 0.47% 5.2%
Enterococcus faecalis 2 0.24% 2.6%
Escherichia coli 5 0.6% 6.5%
Escherichia coli ESBL 2 0.24% 2.6%
Enterobacter cloaceae 4 0.47% 5.2%
Enterobacter aerogenes 3 0.35% 3.9%
Acinetobacter baumanii 2 0.24% 2.6%
Citrobacter freundii 2 0.24% 2.6%
Streptococcus anginosus 2 0.24% 2.6%
Pseudomonas aeruginosa 1 0.12% 1.3%
Cutibacterium acnes 3 0.35% 3.9%
Candida albicans 1 0.12% 1.3%
  1. MRCNS, methicillin-resistant coagulase-negative staphylococci (strain resistant to all beta-lactam antibiotics: penicillins, penicillins with B-lactamase inhibitor, cephalosporins and carbapenems)
  2. MRSA, methicillin-resistant Staphylococcus aureus (resistant to all beta-lactam antibiotics: penicillins with inhibitors, cephalosporins, monobactams, carbapenems, except for ceftaroline)
  3. ESBL, train with Extended Spectrum Beta-Lactamase